Evaluation of local measurement-driven adjustments of modelled cloud-free atmospheric photolysis rate coefficients

Photolysis rate constants (j-values) play a crucial role in atmospheric chemistry modelling, but capturing the variability in local conditions needed for their accurate simulation is computationally challenging. One approach is to adjust modelled clear-sky estimates using ratios of measured-to-modelled j-values of a reference photolysis, typically j(NO2) or j(O1D). However, application of such adjustments to other photolysis reactions introduces uncertainty. Using spectral radiometer data from the UK, this study examines how hourly measurement driven adjustment factors (MDAF) across a set of 12 photolysis reactions group together using cluster analysis, and evaluates the uncertainties in using j(NO2) and j(O1D)-derived MDAF values to adjust modelled j-values of other photolysis reactions. The NO2-MDAF reference is suitable for adjusting photolysis reactions that absorb at λ > 360 nm (HONO, methylglyoxal, ClNO2, ClONO2 → Cl), which are largely independent of solar zenith angle and total ozone column (<31% error). In particular, NO2-MDAF is a good reference for j(HONO) and j(ClNO2). The O1D-MDAF performed better at adjusting modelled j-values for species that predominantly photodissociate at λ < 350 nm, such as HNO3, H2O2, CH3CHO, HCHO → H, HCHO → H2 and ClONO2 → ClO (errors ≤ 30%). However, j(O1D) radiometers require more data processing to account for local conditions. The maximum error determined using NO2-MDAF was within a factor of two (91% for j(H2O2)), which may still be acceptable in some instances. It is important that MDAFs are used to improve accuracy and uncertainty in simulated j-values caused by variation in local conditions

An efficient field and laboratory workflow for plant phylotranscriptomic projects

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/141349/1/aps31600128.pd

The MindfulBreather: Motion Guided Mindfulness.

For millennia, humans have focused their attention on the breath to develop mindfulness, but finding a scientific way to harness mindful breathing has proven elusive. Existing attempts to objectively measure and feedback on mindfulness have relied on specialist external hardware including electroencephalograms or respirometers that have been impractical for the majority of people learning to meditate. Consequently, training in the key skill of breath-awareness has lacked practical objective measures and guidance to enhance training. Here, we provide a brief technology report on an invention, The MindfulBreather® that addresses these issues. The technology is available to download embedded in a smartphone app that targets, measures and feedbacks on mindfulness of breathing in realtime to enhance training. The current article outlines only the technological concept with future studies quantifying efficacy, validity and reliability to be reported elsewhere. The MindfulBreather works by generating Motion Guided Mindfulness through interacting gyroscopic and touchscreen sensors in a three phase process: Mindfulness Induction (Phase I) gives standardized instruction to users to place their smartphone on their abdomen, breathe mindfully and to tap only at the peak of their inhalation. The smartphone's gyroscope detects periodic tilts during breathing to generate sinusoidal waveforms. Waveform-tap patterns are analyzed to determine whether the user is mindfully tapping only at the correct phase of the breathing cycle, indicating psychobiological synchronization. Mindfulness Maintenance (Phase II) provides reinforcing pleasant feedback sounds each time a breath is mindfully tapped at the right time, and the App records a mindful breath. Lastly, data-driven Insights are fed back to the user (Phase III), including the number of mindful breaths tapped and breathing rate reductions associated with parasympathetic engagement during meditation. The new MGM technology is then evaluated and contrasted with traditional mindfulness approaches and a novel Psychobiological Synchronization Model is proposed. In summary, unlike existing technology, the MindfulBreather requires no external hardware and repurposes regular smartphones to deliver app-embedded Motion-Guided Mindfulness. Technological applications include reducing mindwandering and down-regulation of the brain's default mode through enhanced mindful awareness. By objectively harnessing breath awareness, The MindfulBreather aims to realize the ancient human endeavor of mindfulness for the 21st century

Curbing the hepatitis C virus epidemic in Pakistan: The impact of scaling up treatment and prevention for achieving elimination

Background: The World Health Organization (WHO) has developed a global health strategy to eliminate viral hepatitis. We project the treatment and prevention requirements to achieve the WHO HCV elimination target of reducing HCV incidence by 80% and HCV-related mortality by 65% by 2030 in Pakistan, which has the second largest HCV burden worldwide.Methods: We developed an HCV transmission model for Pakistan, and calibrated it to epidemiological data from a national survey (2007), surveys among people who inject drugs (PWID), and blood donor data. Current treatment coverage data came from expert opinion and published reports. The model projected the HCV burden, including incidence, prevalence and deaths through 2030, and estimated the impact of varying prevention and direct-acting antiviral (DAA) treatment interventions necessary for achieving the WHO HCV elimination targets.Results: With no further treatment (currently ∼150 000 treated annually) during 2016-30, chronic HCV prevalence will increase from 3.9% to 5.1%, estimated annual incident infections will increase from 700 000 to 1 100 000, and 1 400 000 HCV-associated deaths will occur. To reach the WHO HCV elimination targets by 2030, 880 000 annual DAA treatments are required if prevention is not scaled up and no treatment prioritization occurs. By targeting treatment toward persons with cirrhosis (80% treated annually) and PWIDs (double the treatment rate of non-PWIDs), the required annual treatment number decreases to 750 000. If prevention activities also halve transmission risk, this treatment number reduces to 525 000 annually.Conclusions: Substantial HCV prevention and treatment interventions are required to reach the WHO HCV elimination targets in Pakistan, without which Pakistan\u27s HCV burden will increase markedly

The Importance of Capturing Local Measurement-Driven Adjustment of Modelled <i>j</i>(NO₂)

Accurate photolysis rate constants are essential for simulation of local air quality but their values can vary substantially with changes in local meteorological and surface conditions. This study demonstrates the use of local radiometer measurements for capturing via hourly measurement-driven adjustment factors (MDAF) the temporal resolution needed to adjust clear-sky or cloud-free model estimates of j(NO2). Measurements simultaneously at two sites in the UK (Auchencorth Moss and Manchester) showed that TUV (v5.3) model estimates of j(NO2)↓ in cloud-free conditions (used as an example of modelled j-values) were, on average, approximately 45% larger than measured j(NO2)↓, which would lead to substantial model bias in the absence of local adjustment. At Auchencorth Moss, MDAF values based on 4π and 2π radiometer inlets generally agreed very well with each other (<6% average difference). However, under conditions of particularly high surface albedo (such as snow cover), increased upwelling local diffuse radiation yielded an MDAF derived using total radiation (sum of ↓ and ↑ components) ~40% larger than the MDAF derived using only ↓ radiation. The study has demonstrated: (1) the magnitude of potential impact of local conditions—principally cloud cover, but also changes in surface albedo—on assumed j-values; (2) that whilst annual mean MDAF values are similar at Auchencorth Moss and Manchester, there is no contemporaneous correlation between them at hourly resolution; hence MDAF values derived at one site cannot readily be applied at another site. These data illustrate the need to routinely deploy long-term radiometer measurements alongside compositional measurements to support atmospheric chemistry modelling

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer

The PI3K/AKT/mTOR pathway is frequently activated in advanced prostate cancer, due to loss of the tumour suppressor PTEN, and is an important axis for drug development. We have assessed the molecular and functional consequences of pathway blockade by inhibiting AKT and mTOR kinases either in combination or as individual drug treatments. In established prostate cancer cell lines, a decrease in cell viability and in phospho-biomarker expression was observed. Although apoptosis was not induced, a G1 growth arrest was observed in PTEN null LNCaP cells, but not in BPH1 or PC3 cells. In contrast, when the AKT inhibitor AZD7328 was applied to patient-derived prostate cultures that retained expression of PTEN, activation of a compensatory Ras/MEK/ERK pathway was observed. Moreover, whilst autophagy was induced following treatment with AZD7328, cell viability was less affected in the patient-derived cultures than in cell lines. Surprisingly, treatment with a combination of both AZD7328 and two separate MEK1/2 inhibitors further enhanced phosphorylation of ERK1/2 in primary prostate cultures. However, it also induced irreversible growth arrest and senescence.Ex vivo treatment of a patient-derived xenograft (PDX) of prostate cancer with a combination of AZD7328 and the mTOR inhibitor KU-0063794, significantly reduced tumour frequency upon re-engraftment of tumour cells.The results demonstrate that single agent targeting of the PI3K/AKT/mTOR pathway triggers activation of the Ras/MEK/ERK compensatory pathway in near-patient samples. Therefore, blockade of one pathway is insufficient to treat prostate cancer in man

The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers

Background: Cannabidiol has potential therapeutic benefits for people with psychiatric disorders characterised by reward function impairment. There is existing evidence that cannabidiol may influence some aspects of reward processing. However, it is unknown whether cannabidiol acutely affects brain function underpinning reward anticipation and feedback. Hypotheses: We predicted that cannabidiol would augment brain activity associated with reward anticipation and feedback. Methods: We administered a single 600 mg oral dose of cannabidiol and matched placebo to 23 healthy participants in a double-blind, placebo-controlled, repeated-measures design. We employed the monetary incentive delay task during functional magnetic resonance imaging to assay the neural correlates of reward anticipation and feedback. We conducted whole brain analyses and region-of-interest analyses in pre-specified reward-related brain regions. Results: The monetary incentive delay task elicited expected brain activity during reward anticipation and feedback, including in the insula, caudate, nucleus accumbens, anterior cingulate and orbitofrontal cortex. However, across the whole brain, we did not find any evidence that cannabidiol altered reward-related brain activity. Moreover, our Bayesian analyses showed that activity in our regions-of-interest was similar following cannabidiol and placebo. Additionally, our behavioural measures of motivation for reward did not show a significant difference between cannabidiol and placebo. Discussion: Cannabidiol did not acutely affect the neural correlates of reward anticipation and feedback in healthy participants. Future research should explore the effects of cannabidiol on different components of reward processing, employ different doses and administration regimens, and test its reward-related effects in people with psychiatric disorders

Changing supersites: Assessing the impact of the southern UK EMEP supersite relocation on measured atmospheric composition

In January 2016 the United Kingdom's southern European Monitoring and Evaluation Programme (EMEP) level-2 air pollution monitoring 'supersite' was relocated from Harwell, Oxfordshire to Chilbolton Observatory, Hampshire. As no co-location study was undertaken, this work retrospectively investigates whether the supersite relocation has led to discontinuities in the time series of concentrations of commonly studied gaseous pollutants (NOx, NH3, SO2 and O3) and particulate matter (PM2.5 and PM10). Two years of measurements pre- and post-relocation (2014–15 and 2016–17 respectively) were analysed in conjunction with meteorological variables and local emission data. The deweather package was applied to the concatenated time series to minimise the influence of meteorology. Similar average concentrations of PM2.5, PM10, SO2 and O3 were observed, but there were substantial differences in that of NOx and NH3 (increase by factors of ~1.6 and ~3, respectively). The considerably higher NH3 concentrations at Chilbolton are attributed to the close proximity of mixed farmland, in particular to a strong south-westerly source contributing to ~50% of the annual average. NOx and PM concentrations in easterly winds arriving at Chilbolton are ~2.7 and ~1.5 times larger than at Harwell, from sources including the M3 motorway and Greater London. Westerly concentrations of NOx remain similar, therefore despite a higher frequency of westerly wind, annual mean concentrations are larger. Lower concentrations of PM arriving from the west result in similar annual averages. The secondary inorganic and black carbon components of PM were broadly similar between the sites. The differences in average NOx and NH3 at Chilbolton must be taken into account when considering long-term regional trends based on the southern UK supersite data

Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination

Background: The World Health Organization (WHO) has developed a global health strategy to eliminate viral hepatitis. We project the treatment and prevention requirements to achieve the WHO HCV elimination target of reducing HCV incidence by 80% and HCV-related mortality by 65% by 2030 in Pakistan, which has the second largest HCV burden worldwide. Methods: We developed an HCV transmission model for Pakistan, and calibrated it to epidemiological data from a national survey (2007), surveys among people who inject drugs (PWID), and blood donor data. Current treatment coverage data came from expert opinion and published reports. The model projected the HCV burden, including incidence, prevalence and deaths through 2030, and estimated the impact of varying prevention and direct-acting antiviral (DAA) treatment interventions necessary for achieving the WHO HCV elimination targets. Results: With no further treatment (currently ?150 000 treated annually) during 2016�30, chronic HCV prevalence will increase from 3.9% to 5.1%, estimated annual incident infections will increase from 700 000 to 1 100 000, and 1 400 000 HCV-associated deaths will occur. To reach the WHO HCV elimination targets by 2030, 880 000 annual DAA treatments are required if prevention is not scaled up and no treatment prioritization occurs. By targeting treatment toward persons with cirrhosis (80% treated annually) and PWIDs (double the treatment rate of non-PWIDs), the required annual treatment number decreases to 750 000. If prevention activities also halve transmission risk, this treatment number reduces to 525 000 annually. Conclusions: Substantial HCV prevention and treatment interventions are required to reach the WHO HCV elimination targets in Pakistan, without which Pakistan�s HCV burden will increase markedly